Article Details

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the ... - BioSpace

Retrieved on: 2022-01-10 13:31:37

Tags for this article:

Click the tags to see associated articles and topics

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the ... - BioSpace. View article details on hiswai:

Excerpt

CHICAGO, Jan. 10, 2022 /PRNewswire/ -- Cour Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up